On Friday, Relay Therapeutics Inc (NASDAQ: RLAY) was -6.67% drop from the session before settling in for the closing price of $3.45. A 52-week range for RLAY has been $1.77 – $10.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 21.05%. With a float of $129.27 million, this company’s outstanding shares have now reached $170.48 million.
The extent of productivity of a business whose workforce counts for 261 workers is very important to gauge. In terms of profitability, gross margin is -12.15%, operating margin of -4927.05%, and the pretax margin is -4341.53%.
Relay Therapeutics Inc (RLAY) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Relay Therapeutics Inc stocks. The insider ownership of Relay Therapeutics Inc is 24.60%, while institutional ownership is 83.63%. The most recent insider transaction that took place on Apr 30 ’25, was worth 32,217. In this transaction an insider of this company sold 10,739 shares at a rate of $3.00, taking the stock ownership to the 390,081 shares. Before that another transaction happened on Apr 28 ’25, when Company’s See remarks sold 1,364 for $3.17, making the entire transaction worth $4,324. This insider now owns 400,820 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 21.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.83% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
You can see what Relay Therapeutics Inc (RLAY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 19.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 71.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
The latest stats from [Relay Therapeutics Inc, RLAY] show that its last 5-days average volume of 1.42 million was inferior to 2.32 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 50.52%. Additionally, its Average True Range was 0.24.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 44.21%, which indicates a significant decrease from 48.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.06% in the past 14 days, which was lower than the 78.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.93, while its 200-day Moving Average is $4.56. Now, the first resistance to watch is $3.35. This is followed by the second major resistance level at $3.48. The third major resistance level sits at $3.55. If the price goes on to break the first support level at $3.14, it is likely to go to the next support level at $3.07. Assuming the price breaks the second support level, the third support level stands at $2.94.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
There are 171,445K outstanding shares of the company, which has a market capitalization of 552.05 million. As of now, sales total 10,010 K while income totals -337,710 K. Its latest quarter income was 7,680 K while its last quarter net income were -77,070 K.
